CEAT Limited has received an order from the Food and Drug Administration (FDA), Maharashtra, temporarily suspending its licence to procure methanol. The suspension is scheduled to take effect from September 1, 2026 to September 15, 2026. This regulatory development follows alleged violations of competent person norms under the Maharashtra Poisons Rules, 1972.

Regulatory details

The company disclosed the receipt of the order on August 19, 2026, pursuant to Regulation 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The FDA Maharashtra issued the communication to the company’s authorized officers on August 18, 2026.

The suspension cites alleged contraventions under Rules 9 and 11 of the Maharashtra Poisons Rules, 1972, specifically relating to license conditions concerning competent person norms. Methanol is a critical chemical used in the company’s industrial and manufacturing processes for tyre production.

Operational impact

CEAT stated that the suspension order has not yet become effective as of the disclosure date. The company confirmed that it has already made alternate arrangements to procure methanol in compliance with applicable rules. Furthermore, CEAT noted that the issues raised in the suspension order have been addressed by the company.

Accordingly, management anticipates no material adverse impact on the company’s financial position, operations, or overall business activities during the suspension period. The temporary nature of the licence loss suggests a contained regulatory setback rather than a long-term operational disruption.

Shareholders of CEAT have authorised the company to raise debt capital through a private placement of Non-Convertible Debentures (NCDs) up to ₹1,000 crore. The resolution was passed as a special resolution during the company’s 67th Annual General Meeting (AGM) held via video conferencing on August 17, 2026.

Alongside the capital raising mandate, shareholders approved the declaration of a final dividend of ₹35 per equity share for FY26. The payout represents a significant return to investors, with the resolution receiving overwhelming support from both promoter and public shareholders.

Voting Results and Shareholder Sentiment

The AGM saw high participation rates across key resolutions. For the NCD issuance, 99.9995% of votes polled were in favour, with only 147 votes cast against out of over 30 million votes polled. Similarly, the dividend declaration received 99.9999% affirmative votes.

Board and Governance Updates

The meeting also addressed board composition and statutory appointments. Shareholders re-appointed Mr. Anant Vardhan Goenka as a Non-Executive, Non-Independent Director upon his retirement by rotation. This resolution passed with 90.68% support, though it faced notable dissent from institutional investors, who voted against at a rate of 25.42%.

Additionally, shareholders approved the continuation of Mr. Paras Kumar Chowdhary as a Non-Executive, Non-Independent Director. This special resolution secured 97.51% of votes polled. The remuneration for M/s D.C. Dave & Co., the company’s Cost Auditor for FY26, was also ratified with near-unanimous support.

What the Numbers Show

The voting data reveals a divergence in shareholder sentiment regarding governance versus financial matters. While financial resolutions such as the dividend payout and NCD issuance enjoyed near-total consensus (>99.9%), the re-appointment of Mr. Anant Vardhan Goenka saw significantly higher opposition, particularly from the public-institution category where nearly a quarter of votes were cast against. This suggests institutional investors may be exercising greater scrutiny on board continuity compared to capital allocation decisions.